Employees (10 or More Rate)

The Employees (10 or More Rate) is a specific 15% tax credit tier applied to the qualified research expenditures of New York life sciences companies maintaining a quarterly average headcount of ten or more persons. Firms falling below this employment threshold are eligible for an enhanced 20% rate, a bifurcated structure designed to provide aggressive capital support to the smallest startups while incentivizing scaling enterprises to maintain robust internal research teams.

Theoretical Foundation and Legislative Intent of the Tiered Credit System

The New York State Life Sciences Research and Development Tax Credit Program represents a strategic fiscal intervention by the state to foster a self-sustaining innovation ecosystem. At the heart of this program is the differentiation between the 15% and 20% credit rates, categorized by the Employees (10 or More) threshold. This policy design reflects a sophisticated understanding of the life sciences business cycle. Early-stage biotechnology and pharmaceutical firms typically face a valley of death—a period of high capital intensity and zero revenue during the initial years of drug discovery or medical device prototyping. By offering a 20% credit to firms with fewer than ten employees, the state provides a higher subsidy for the most vulnerable, micro-scale entities. Once a firm scales beyond nine employees, the rate transitions to 15%, which remains significantly more generous than general R&D credits, reflecting the high value the state places on mature research operations that provide stable, high-paying jobs.

This tiered system is governed by Tax Law Section 43, which provides the statutory basis for the credit. The legislation specifically targets new businesses to ensure that the $10 million annual statewide allocation is directed toward growth-stage innovation rather than established corporate giants. The interaction between the 15% rate and the $500,000 annual cap creates a natural progression for companies. A company utilizing the 15% rate (10 or more employees) reaches the $500,000 annual limit at approximately $3.33 million in qualified research expenditures (QREs). In contrast, a smaller firm utilizing the 20% rate hits the same cap at $2.5 million in spend. This mechanism effectively allows the state to support a broader range of company sizes while maintaining a strict ceiling on the fiscal impact per taxpayer.

The broader context of this credit is New York’s $620 million Life Science Initiative, a multi-faceted program aimed at transforming the state into a global biotechnology hub. The tax credit is a primary component of this initiative, acting as the pull factor to attract and retain firms that might otherwise gravitate toward established clusters in Boston or San Francisco. By making the credit fully refundable, New York provides immediate liquidity, allowing pre-revenue firms to reinvest in lab equipment, specialized supplies, and technical talent. This liquidity is paramount for companies with 10 or more employees, as payroll costs at this scale often represent the single largest overhead expense.

Regulatory Guidance on Determining the Employee Headcount

The application of the 15% rate hinges entirely on a precise calculation of the company’s average workforce. The New York State Department of Taxation and Finance, in coordination with Empire State Development (ESD), has issued specific guidance on how to determine if a company employs 10 or more persons. This is not a simple snapshot of the payroll on the last day of the year; rather, it is a sustained average that accounts for the fluctuations common in high-growth startups.

The Quarterly Averaging Formula

According to the official Life Sciences Research and Development Tax Credit Program FAQ and administrative guidelines, the number of persons employed during a year is an average of full-time employees, excluding general executive officers, employed throughout the year. The state mandates that the number of individuals employed on four specific dates—March 31, June 30, September 30, and December 31—must be added together and divided by four. If the resulting quotient is 10.0 or higher, the 15% rate applies. If it is 9.99 or lower, the 20% rate applies.

Quarter End Date	Employee Count (Example)	Qualification Status
March 31	8	Below Threshold
June 30	10	At Threshold
September 30	12	Above Threshold
December 31	12	Above Threshold
Annual Average	10.5	Qualifies for 15% Rate

This averaging method prevents companies from temporarily inflating their headcount at the end of the year just to change their tax position. It also protects companies that may have started the year with a small team but grew rapidly, as the average might still keep them in the 20% tier for their first year of eligibility. The law explicitly states that job thresholds are applicable for each year that a company applies. This means a company could potentially shift between the 20% and 15% rates across the three-year eligibility window as their workforce expands or contracts.

Definition of a Full-Time Employee (FTE)

Guidance from the revenue office clarifies that a full-time employee is an individual in a job consisting of at least 35 hours per week. However, the program also recognizes the use of Full-Time Equivalents (FTEs). Two or more employees who are in jobs that together constitute the equivalent of at least 35 hours per week are counted as one full-time employee. This flexibility is critical for research laboratories that often utilize part-time technicians or specialized consultants who do not work a traditional 40-hour week but contribute significantly to the R&D mission.

The General Executive Officer Exclusion

A vital nuance in the headcount calculation is the exclusion of general executive officers. The state defines these as individuals who are appointed by the board of directors and are responsible for the overall management of the corporation, such as the Chairman, President, Vice President, Secretary, or Treasurer. Even if these individuals are actively performing laboratory research, they do not count toward the 10 or more threshold. This exclusion ensures that the tiered rate is sensitive to the size of the technical and support staff rather than the leadership layer. For a small biotech with two founders and eight scientists, the exclusion of the founders could keep the company in the 20% rate category, even though the total headcount is ten.

The Statutory Definition of a Qualified Life Sciences Company

To utilize either the 15% or 20% rate, an entity must be certified by ESD as a qualified life sciences company. This involves meeting two distinct sets of criteria: the Life Sciences test and the New Business test. These definitions are strictly enforced through the application process and verified via the Department of Economic Development.

The Life Sciences Test

The entity must devote the majority of its efforts to research, development, technology transfer, or commercialization within a recognized life sciences field. The Department of Taxation and Finance provides an expansive list of eligible fields to accommodate the modern diversity of biotechnology.

Life Science Field	Description of Eligible Activities
Agricultural Biotechnology	Development of genetically modified crops, biofuels, and bio-pesticides.
Biopharmaceuticals	Discovery and development of drugs derived from biological sources.
Genomics	Sequencing and analysis of genomes for therapeutic or diagnostic use.
Medical Devices	Design and prototyping of instruments for disease diagnosis or treatment.
Bioinformatics	Using computational tools to analyze biological and biochemical data.
Medical Nanotechnology	Utilizing nanoscale materials for targeted drug delivery or imaging.

The majority of efforts requirement is typically measured by expenditures or employee time allocation. If a company has multiple business lines, it must prove that the life sciences component is its primary driver of value and activity.

The New Business Requirement (Tax Law 210-b(1)(f))

The 15% rate for companies with 10 or more employees is explicitly reserved for new businesses. This term is a legal term of art in New York Tax Law and carries several restrictive conditions intended to target independent startups.

The Five-Year Rule: The company must not have been a taxpayer in New York State for more than five years prior to the taxable year in which it first claims the credit.

Ownership Restriction: The entity cannot have more than 50% of its ownership or control, directly or indirectly, held by another company that is already a New York taxpayer. This prevents large pharmaceutical companies from creating shell startups to harvest credits.

Substantial Similarity: The business must not be substantially similar in ownership and operation to another company that is or was previously a New York taxpayer. This prevents phoenix companies from closing and reopening under a new name to restart the three-year credit clock.

Related Person Exclusion: The Department of Economic Development will not certify any entity that has been, within the preceding 60 months, a related person to another entity that does not meet the new business test.

For firms at the 10+ employee level, these new business tests are often where compliance becomes difficult. Scaling firms often receive investment from larger entities; if that investment crosses the 50% control threshold, the entity may lose its new business status and, consequently, its eligibility for the 15% credit.

Analysis of Qualified Research Expenditures (QREs)

The credit is calculated as a percentage (15% or 20%) of qualified research expenditures incurred in New York. While the state borrows heavily from the federal definition of QREs under Internal Revenue Code Section 41, there is a fundamental departure regarding third-party research.

Eligible Expense Categories

There are three primary buckets of expenses that qualify for the New York Life Sciences Credit:

Wages: Salaries paid to employees for qualified services. This includes the bench scientists performing experiments, the supervisors overseeing the lab, and the support staff directly assisting in research. It does not include general administrative, legal, or marketing staff.

Supplies: This covers tangible property used in the conduct of research, such as reagents, chemicals, lab glassware, and specialized materials for prototypes. It explicitly excludes land and property subject to depreciation (capital assets).

Computer Rentals: Payments made to another person for the right to use computers in the conduct of research. In the modern biotech era, this primarily refers to cloud computing costs (e.g., AWS, Google Cloud) used for data analysis, genomic sequencing, or drug modeling, provided the use occurs within New York.

The Contract Research Exclusion: A Strategic Barrier

The most significant difference between the New York Life Sciences Credit and the general Federal R&D Credit is that New York excludes contract research expenses. Under federal rules, companies can generally claim 65% of the fees paid to outside Clinical Research Organizations (CROs) or contractors. New York forbids this entirely for this specific program.

This exclusion has a direct impact on the 10 or More employee threshold. By excluding contract research, the state forces companies to hire internal employees if they want to capture the tax credit. A firm with nine employees that is considering outsourcing a project to an out-of-state CRO must weigh the cost of that contract against the benefit of hiring a tenth internal employee in New York. While hiring the tenth employee drops the credit rate from 20% to 15%, it also converts what would have been an ineligible contract expense into an eligible wage expense. This creates a powerful gravitational pull, encouraging firms to build permanent laboratory infrastructure in New York rather than operating as virtual biotech companies.

Local State Revenue Office Guidance: Administrative Compliance

To successfully claim the 15% credit, companies must navigate a dual-agency administrative process. Empire State Development (ESD) manages the eligibility and allocation of the credit, while the Department of Taxation and Finance manages the filing and refund process.

The Application and Certification Process

Firms must first apply to ESD for a Certificate of Tax Credit. This application requires a detailed breakdown of the company’s new business status, its life sciences activities, its headcount (demonstrating the 10+ threshold), and its projected QREs.

First-Come, First-Served: The $10 million annual statewide pool is allocated in the order that complete applications are filed. If the pool is exhausted, subsequent applicants are moved to the next year’s allocation.

Three-Year Window: The credit is only available for three consecutive years. A company must apply each year to receive a new certificate for that year’s expenses.

The Certificate: The ESD issues a certificate that specifies the authorized credit amount and the tax year. This certificate is the golden ticket required for the tax return.

Filing the Tax Return

Once the certificate is issued, the company must file the appropriate forms with their New York tax return.

Article 9-A Filers (Corporations): Must file Form CT-648, Life Sciences Research and Development Tax Credit.

Article 22 Filers (Partnerships, S-Corps, Individuals): Must file Form IT-648, Life Sciences Research and Development Tax Credit.

The Department of Taxation and Finance emphasizes that the credit cannot reduce the tax liability below the fixed dollar minimum tax for corporations. However, because the credit is fully refundable, any amount exceeding that minimum is paid out as a cash refund. This is a critical distinction from other credits that might only allow for a carryforward, which is useless for a startup with no current tax liability.

Documentation and Audit Standards

The Revenue Office provides strict guidelines on documentation. To maintain the 15% rate, a company must keep contemporaneous records that were created at the time the research was performed.

Time Tracking: Detailed logs showing the hours each employee spent on qualified services.

Employment Records: Payroll summaries and organizational charts proving the quarterly average headcount stayed at or above ten.

Expense Nexus: Invoices and receipts proving that supplies were purchased for and used in New York.

Comparison with Other New York R&D Incentives

A company with 10 or more employees must determine if the Life Sciences Credit is the most efficient incentive for its profile. New York offers several overlapping programs, but a company cannot use the same expenses for multiple credits.

The Excelsior Jobs Program R&D Credit

The Excelsior Jobs Program is a much larger, 10-year program that offers a package of credits for job creation and investment.

The R&D Component: Offers a credit of 50% of the portion of the federal R&D credit attributable to New York activities, capped at 6% of research expenditures (8% for green projects).

Comparison: The Life Sciences Credit (15%) is significantly more generous on a per-dollar-spent basis than the Excelsior R&D credit (6%). However, the Excelsior program also includes a Jobs Tax Credit (up to 6.85% of wages) and an Investment Tax Credit (2%). A scaling company with a large workforce and significant capital investment might find the total Excelsior package more valuable over a 10-year period than the 3-year Life Sciences credit.

The NYC Biotechnology Tax Credit

For companies located within the five boroughs of New York City, a separate local credit is available.

Headcount Threshold: The NYC credit is available to firms with 100 or fewer full-time employees.

Rate and Cap: It offers various credits for hiring and training, capped at $250,000 per taxpayer per year.

Synergy: While a firm cannot double-dip expenses, a biotech firm in Long Island City could theoretically utilize the state’s 15% life sciences credit for its research wages and look for other local incentives for its workforce training.

Feature	Life Sciences R&D Credit	Excelsior R&D Credit	NYC Biotechnology Credit
Primary Rate	15% (for 10+ employees)	6% of expenditures	Varies by job creation
Duration	3 Consecutive Years	10 Years	Annual Application
Refundability	Fully Refundable	Fully Refundable	Fully Refundable
Maximum Cap	$500,000 / Year	None (determined by ESD)	$250,000 / Year

Statistical Evidence of Program Efficacy

The Department of Economic Development’s annual reports provide insights into the real-world impact of the Life Science Initiative and the tiered credit system. These statistics validate the state’s focus on the 10+ employee threshold as a marker of sectoral health.

Sector-Wide Growth Metrics (2017–2024)

Employment Growth: The life sciences sector in New York experienced an 18.5% increase in total jobs between 2017 and 2022. This growth rate significantly outperformed the state’s overall private sector and exceeded the national private sector job growth rate of 13.3% during the same timeframe.

Venture Capital Momentum: Since the launch of the initiative, venture investment in New York’s life sciences firms has surged. The state now ranks second in the nation for NIH funding, receiving approximately $3.6 billion annually.

Company Retention: The initiative has resulted in the formation or retention of at least 32 major new companies in New York.

Credit Utilization: Between April 2022 and October 2023, approximately $3.66 million in Life Science R&D tax credits were issued against $34.68 million in qualified expenditures. This indicates that the 15% and 20% rates are being actively utilized, though the $10 million annual cap still has capacity for new entrants.

Regional Cluster Performance

The impact is heavily concentrated in certain geographic hubs. New York City, particularly the biotech corridor in Manhattan and Long Island City, has seen the most rapid growth, with over 3.1 million square feet of lab space now active. However, upstate hubs like the Roswell Park Comprehensive Cancer Center in Buffalo and the Empire Discovery Institute in Rochester also play a critical role in the 10+ employee tier, as they often house the manufacturing-adjacent life sciences firms that require larger headcounts.

Case Study: Transitioning from the 20% to the 15% Rate

To understand the practical application of the revenue office guidance, consider the case of GenoLink Therapeutics, a fictional biotech startup in Albany.

Year 1: The Micro-Startup Phase

In its first year, GenoLink has an average headcount of 4 employees (excluding the CEO).

NY QREs (Wages + Supplies): $1,000,000

Applied Rate: 20% (Fewer than 10 employees)

Total Credit: $200,000 (Refunded in cash)

Year 2: The Scaling Phase

GenoLink closes a Series A funding round and hires 8 new scientists.

Headcount Calculation:

Q1: 4

Q2: 12

Q3: 12

Q4: 12

Average: (4+12+12+12) / 4 = 10.0

NY QREs: $3,000,000

Applied Rate: 15% (10 or more employees)

Preliminary Credit: $450,000

Net Impact: Even though the rate dropped from 20% to 15%, the increased expenditure resulted in a much larger total refund.

Year 3: Reaching the Cap

GenoLink expands to 15 employees and increases its research activities further.

NY QREs: $4,500,000

Applied Rate: 15%

Preliminary Credit: $675,000

Actual Credit: $500,000 (Limited by the annual statutory cap)

This scenario demonstrates how the 10 or More threshold naturally shifts as a company matures. For GenoLink, the 15% rate became the anchor for its most expensive year, providing a half-million-dollar infusion that effectively subsidized nearly 4 scientists’ salaries.

Challenges and Controversies in Implementation

While the program is highly regarded, the 15% rate and its associated rules have faced criticism and complexity in practice.

Entity Type Restrictions

A point of confusion for many venture-backed startups is the eligibility of different entity types. Some guidance suggests that Delaware C-Corporations may face hurdles if they are not properly registered and authorized to do business in New York. While Article 9-A (which governs corporations) clearly includes the credit, the new business test’s focus on ownership can be tricky for startups that have been spun out of universities or larger entities.

The Cliff Effect

Critics of tiered systems often point to cliff effects, where hiring one more employee can result in a net loss of tax benefits. As calculated previously, a firm with exactly $2.5 million in QREs would prefer the 20% rate ($500k credit) over the 15% rate ($375k credit). This potentially creates a disincentive to hire the tenth employee until the company is ready to significantly increase its spending. However, the Department of Taxation and Finance has maintained that the averaging method and the exclusion of executive officers mitigate this effect, as it is difficult for a company to game its headcount with such precision across four quarters.

Statewide Cap Competition

Because the $10 million statewide cap is allocated on a first-come, first-served basis, larger firms with 10+ employees—who often have more sophisticated accounting departments—might be more efficient at filing early than micro-startups. This could lead to a situation where the 10 or More firms exhaust the fund, leaving smaller firms in the Fewer than 10 category without an allocation despite their higher theoretical rate.

Final Thoughts

The Employees (10 or More Rate) of 15% is a vital tool in New York’s economic development toolkit, representing a balanced approach to industrial policy. By providing a clear, refundable incentive for firms to maintain a workforce of ten or more persons, the state has successfully incentivized the transition from academic research to commercial scale-up. The administrative guidance provided by the Department of Taxation and Finance and Empire State Development ensures that this credit is targeted toward genuine new businesses that contribute to the local economy through internal hiring and supply-chain spending.

For the life sciences executive, the 15% rate should be viewed as a foundational element of a New York-based financial strategy. It effectively lowers the cost of technical talent, mitigates the risk of large-scale R&D expenditures, and provides a predictable source of liquidity during the critical first three years of growth. As the life sciences sector continues to evolve with advances in cell therapy, gene editing, and medical nanotechnology, New York’s tiered credit system stands as a model for how state governments can proactively shape high-tech industries. The success of the program—evidenced by the 18.5% job growth in the sector—suggests that the 10-employee threshold is not just an arbitrary tax marker, but a successful pivot point for a scaling innovation economy. Future iterations of the program may see adjustments to the $500,000 annual cap or the $10 million statewide pool to accommodate the burgeoning demand, but the principle of tiered support based on employment levels remains a cornerstone of the New York life sciences landscape.